[SCHEDULE 13G] Pacira BioSciences, Inc. SEC Filing

Rhea-AI Filing Summary

Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation reported beneficial ownership of 2,395,601 shares of Pacira BioSciences common stock, representing 5.34% of the outstanding class. The filing states the reporting persons have sole voting and sole dispositive power over these shares. It also notes that certain funds managed by Renaissance have the right to receive dividends and proceeds from the sale of the securities. The statement certifies the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

This disclosure crosses the 5% reporting threshold and provides clarity on who controls the position without indicating an activist intent.

Positive

• 2,395,601 shares disclosed, representing 5.34% of Pacira BioSciences common stock
• Sole voting and sole dispositive power explicitly reported for the shares
• Filing clarifies that certain Renaissance-managed funds have rights to dividends and proceeds, improving transparency

Negative

• None.

Insights

Financial Analyst

TL;DR Renaissance reports a passive 5.34% holding (2,395,601 shares) with sole voting/dispositive power; material for disclosure but not an activist signal.

The filing documents a substantial institutional stake equal to 5.34% of Pacira BioSciences common stock, with Renaissance stating both sole voting and dispositive authority over the shares. Because the filing is a Schedule 13G and includes a certification that the position is held in the ordinary course and not to influence control, this is a transparency event rather than an operational or strategic shift by the holder. Investors gain clarity on ownership concentration and who controls voting of this block.

Corporate Governance Expert

TL;DR 5.34% passive stake with sole voting/dispositive power increases governance transparency; filing certifies no intent to influence control.

From a governance perspective, disclosure of sole voting and dispositive power over a >5% position improves market transparency about who will vote this block in shareholder matters. The explicit certification that the securities were not acquired to change or influence control signals a non-activist posture. The filing does not identify any arrangements that would transfer voting authority to third parties, and notes certain managed funds hold rights to dividends and proceeds.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Pacira BioSciences, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

695127100

(CUSIP Number)

04/08/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 695127100

1

Names of Reporting Persons

Renaissance Technologies LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,395,601.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,395,601.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,395,601.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.34 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP No. 695127100

1

Names of Reporting Persons

Renaissance Technologies Holdings Corporation

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,395,601.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,395,601.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,395,601.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.34 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Pacira BioSciences, Inc.
(b)	Address of issuer's principal executive offices: 2000 SIERRA POINT PARKWAY, SUITE 900, BRISBANE, CA 94005
Item 2.
(a)	Name of person filing: This Schedule 13G is being filed by Renaissance Technologies LLC ("RTC") and Renaissance Technologies Holdings Corporation ("RTHC").
(b)	Address or principal business office or, if none, residence: 800 Third Avenue New York, New York 10022
(c)	Citizenship: RTC is a Delaware limited liability company, and RTHC is a Delaware corporation.
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 695127100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2395601
(b)	Percent of class: 5.34 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2395601
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2395601
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Certain funds managed by RTC have the right to receive dividends and proceeds from the sale of the securities which are the subject of this report.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Renaissance Technologies LLC

Signature:	Brian Felczak
Name/Title:	Chief Financial Officer
Date:	08/13/2025

Renaissance Technologies Holdings Corporation

Signature:	Brian Felczak
Name/Title:	Vice President
Date:	08/13/2025

Exhibit Information

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned agrees to the filing on behalf of each of a Statement on Schedule 13G, and all amendments thereto, with respect to the shares of Common Stock, par value $0.001 per share of Pacira BioSciences, Inc.

FAQ

Who filed the Schedule 13G for Pacira BioSciences (PCRX)?

The Schedule 13G was filed by Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation.

How many PCRX shares does Renaissance report owning and what percent is that?

The report states beneficial ownership of 2,395,601 shares, equal to 5.34% of the class.

Does Renaissance have voting authority over the disclosed PCRX shares?

Yes. The filing indicates sole voting power and sole dispositive power with respect to the 2,395,601 shares.

Is Renaissance trying to influence control of Pacira BioSciences?

The filing includes a certification that the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

Do other parties have rights to dividends or sale proceeds for these shares?

The filing notes that certain funds managed by Renaissance have the right to receive dividends and proceeds from the sale of the securities.